Search

The patent application titled "Geometric Configurations For Gastric Residence Systems" discusses advancements in the design and manufacture of gastric residence systems for sustained release of therapeutic agents in the stomach. The invention focuses on extending shelf life, lowering manufacturing costs, and improving system performance when administered to patients. The systems are designed to remain in the stomach for at least 24 hours, releasing therapeutic agents over the desired period. The patent application details the materials, dimensions, and arrangements necessary for the effective functioning of these gastric residence systems. [Extracted from the article]

Recent research from the University of Ghent in Merelbeke, Belgium, focuses on tissue engineering, specifically the fabrication of tubular constructs for in vitro vascular wall models using digital light processing (DLP) of acrylate-endcapped urethane-based (AUP) polymers. The study explores different AUP variants with varying acrylate functionalities and backbones, demonstrating tunable mechanical properties that closely mimic human blood vessels. Surface modifications with gelatin-methacryloyl (GELMA) enhance cytocompatibility, highlighting the potential of AUP polymers for vascular wall modeling. This peer-reviewed research offers insights into the feasibility of creating tunable tubular constructs for biomedical applications. [Extracted from the article]

Researchers from the University of Washington have submitted a patent application for "Enzyme-Loaded Polymeric Nanoparticles And Methods Of Manufacture And Use Of Same" to the USPTO. The application focuses on improving neonatal outcomes by using enzyme-loaded nanoparticles to complement therapeutic hypothermia in treating neonatal hypoxic-ischemic encephalopathy. The method involves increasing the lipophilicity of enzymes through hydrophobic ion pairing to retain their activity within polymeric nanoparticles. This innovative approach aims to address challenges related to enzyme delivery and bioavailability for treating various neurological and non-neurological conditions. [Extracted from the article]

Lyndra Therapeutics Inc. has been issued a patent for materials architecture for gastric residence systems, allowing for the sustained release of drugs or agents in the stomach. The patent describes advancements in the design and manufacture of these systems, providing precise control over performance, stability, safety, and residence time in the gastrointestinal tract. The patent outlines various embodiments of gastric residence systems, including components such as carrier polymers, therapeutic agents, disintegrating linkers, and reinforcing materials. The patent also details methods for manufacturing these systems, emphasizing the customization and tailored architecture of the materials used. [Extracted from the article]

A patent application by inventors from Imam Abdulrahman Bin Faisal University in Saudi Arabia describes a solvent-based method for creating a medicinal nanocomposite to treat cervical and colorectal cancers and combat bacterial infections. The nanocomposite consists of carrier particles of porous silicate material, silver nanoparticles, and a platinum-containing pharmaceutical compound. The method involves aging a reaction mixture, heating, calcining, and mixing to form the nanocomposite, which releases the pharmaceutical compound selectively to cancerous cells while minimizing toxicity to non-cancerous cells. [Extracted from the article]

This document summarizes several U.S. patents related to the use of botanical extracts for medical treatments. One patent discusses a medical device containing boswellic acid, derived from plants, for controlled release of triterpenes or extracts from the Boswellia genus. The device is made from biodegradable materials and can prevent adhesion, repair wounds, or strengthen soft tissue. Other patents describe compositions and methods for treating conditions like Kaposi's sarcoma, Epstein Barr virus, osteoarthritis, inflammation, pain, fungal infections, and cancer using compounds from plants like Boswellia and soybeans. These patents may be useful for researchers exploring natural remedies and alternative treatments for various diseases and conditions. [Extracted from the article]

L.E.A.F. Holdings Group LLC has been granted a patent for alpha polyglutamated antifolates, which can be used to treat diseases like cancer, immune system disorders, and infectious diseases. The patent explains how these antifolates can be delivered directly into cells in a higher-level polyglutamate form, bypassing the need for the cells to convert them. This method aims to address the limitations and resistance often associated with antifolate therapy. The patent also includes claims for a liposomal composition that contains the alpha polyglutamated antifolate, providing detailed information about its composition and potential applications in cancer treatment. [Extracted from the article]

Inventor David B. Masters has filed a patent application for the development of biocompatible protein-based particles for medical devices. The application addresses the limitations of previous devices and proposes the use of protein matrix materials to create cohesive bodies that can be processed into particles. These particles are designed to be biocompatible, biodegradable, and capable of mimicking host tissue composition, promoting tissue growth and integration. The application also describes a method for treating and enhancing joint function by administering particles made from biocompatible proteins, glycosaminoglycans, and biocompatible solvents. The particles can be customized and shaped, and may contain pharmacologically active agents and biocompatible additives. Detailed information on the composition and proportions of the particles is provided in the application. [Extracted from the article]

A patent application has been filed for a composition that could potentially treat acne. The composition contains glycolic acid, gluconolactone, and mandelic acid, among other ingredients, with a total acid content of less than 15%. It can be in the form of a lotion or gel and has a pH level of 3 to 5. The patent application also describes a method of treating acne by applying the composition to the affected skin, aiming to disrupt biofilms and kill bacteria. The composition may also include alpha hydroxy acids, polyhydroxy acids, a glycol, and a salt-tolerant thickening polymer, and may be in the form of a lotion, serum, or contain emollients. [Extracted from the article]

A patent application titled "Methods Suitable For Disrupting A Biofilm, And/Or Killing Bacteria Contained In A Biofilm" has been published online. The application discusses the treatment of acne, both noninflammatory and inflammatory. The inventors propose a composition for acne treatment that includes glycolic acid, gluconolactone, and mandelic acid, among other ingredients. The composition can be in the form of a lotion or gel and has a pH of about 3 to 5. The patent application also mentions the need for effective and well-tolerated acne treatments. It is important to note that this information is based on a patent application and has not been proven or verified. [Extracted from the article]

A patent has been issued to Albert Einstein College of Medicine for transdermal delivery formulations. The patent focuses on the use of transdermal formulations to deliver therapeutic agents to targeted sites in the body, such as the lungs or arthritic joints. The formulations aim to enhance nitric oxide levels, which can reverse inflammation and restore vascular homeostasis. The patent also discusses the role of CD38 in various diseases and conditions, and proposes the use of transdermal formulations to reduce CD38 activity and promote tissue repair. The formulations include curcuminoids and flavonoids, and can be delivered transdermally to bypass the gut and liver. [Extracted from the article]

A patent has been issued for a liposomal composition containing gamma polyglutamated tetrahydrofolates, which can be used to treat diseases such as cancer, immune system disorders, and infectious diseases like HIV and malaria. The composition can be used in combination therapy with other drugs to enhance their effectiveness or reduce side effects. The patent provides detailed information about the specific components and characteristics of the liposomal composition, including its zeta potential, pH levels, and concentrations of substances. It also includes claims about the composition's ability to kill hyperproliferative cells and prepare gamma polyglutamated tetrahydrofolate compositions. [Extracted from the article]

A patent application has been published online by the USPTO for a method to prevent and treat aging-related cognitive impairment and neuroinflammation. The inventors propose administering a compound called ZLN005 to aging or older subjects. They have shown that activating a specific protein improves cognitive performance and reduces neuroinflammation in older animals. The compound can be formulated in various pharmaceutical carriers and the patent application includes specific claims regarding administration and dosage. This method aims to reduce symptoms of aging-related cognitive impairment and neuroinflammation. [Extracted from the article]

A patent application has been published by the USPTO for a drug delivery system developed by inventors from the University of Toronto. The system, called self-microemulsifying drug delivery systems (SMEDDS), uses lecithin to solubilize and deliver poorly water-soluble polar active ingredients. The SMEDDS can be used for various routes of administration and are fully dilutable in aqueous solutions. They can produce drop sizes ranging from 1 to 200 nm and do not contain certain ingredients like short-chain alcohols and PEG-based surfactants. The patent application also mentions the use of low molecular weight organic gelators and coating agents for extended-release and enteric protection. The invention aims to improve the solubility and bioavailability of poorly water-soluble polar solutes. [Extracted from the article]

Johnson & Johnson Consumer Inc. has been issued a patent for methods suitable for disrupting a biofilm and killing bacteria contained in a biofilm. The patent describes a composition for the treatment of acne that includes glycolic acid, gluconolactone, mandelic acid, a glycol, and a salt-tolerant thickening polymer. The composition is applied to the skin and has a pH of about 3 to 5. The inventors state that there is an ongoing need for effective and well-tolerated acne treatments. [Extracted from the article]

Lyndra Therapeutics Inc. has been issued a patent for geometric configurations for gastric residence systems. These systems are designed to deliver therapeutic agents to the stomach and remain there for an extended period of time, releasing the drugs for absorption in the gastrointestinal tract. The patent describes advancements in the design and manufacture of these systems, including methods to extend their shelf life and improve their performance. The systems consist of an elastomer component and multiple carrier polymer-agent components, and they are designed to be retained in the stomach for at least 24 hours while releasing a therapeutically effective amount of the drug. The patent provides detailed descriptions of the various components and configurations of the gastric residence systems. [Extracted from the article]

A patent has been issued to Johnson & Johnson Consumer Inc. for methods suitable for the treatment of acne. The patent describes a composition for the treatment of acne that includes glycolic acid, gluconolactone, mandelic acid, a glycol, and a salt-tolerant thickening polymer. The composition is designed to be left on the skin and can be in the form of a lotion. The patent claims also specify that the composition should have a pH of about 3 to 5 and be substantially free of lactic acid and salicylic acid. The inventors state that there is a need for additional acne treatments that are both effective and well-tolerated by the skin. [Extracted from the article]

A patent application has been published online for a composition and method to treat acne. The composition includes glycolic acid, gluconolactone, and mandelic acid, with a total amount of less than 15% of the composition. It may also contain a glycol and a salt-tolerant thickening polymer. The composition is applied to the skin to disrupt biofilms and kill bacteria associated with acne. It is formulated as a lotion or serum with a pH of 3 to 5 and does not contain lactic acid or salicylic acid. The patent application provides detailed claims and specifications for the composition and its use in treating acne. [Extracted from the article]

A report from the University of Tabriz in Iran discusses research on the use of aqueous biphasic systems (ABSs) containing natural deep eutectic solvents (NADESs) for extracting various substances. The study focused on investigating the phase behavior of ABSs composed of poly(propylene) glycol 400 and NADESs, specifically choline chloride/sucrose. The research examined the extraction capabilities of these ABSs for three commonly used drugs and found that the extraction efficiency depends on the hydrophobicity of the drugs. The study concludes that there is considerable interest in utilizing ABSs with NADESs for extraction purposes. [Extracted from the article]

The patent application titled "Methods For Isolating Target Analytes From Biological Samples Using Atps And Solid Phase Media" describes innovative techniques for concentrating and purifying target analytes, such as nucleic acids, from clinical biological samples. These methods involve the use of Aqueous Two-Phase Systems (ATPS) and solid phase media, such as beads or columns, to effectively remove interfering salts and proteins from the sample matrix. The methods are straightforward, reliable, and efficient, and can be applied to diagnostic tests for cancers and infectious diseases. The patent application was submitted by inventors from Hong Kong, China, Singapore, and the United States. It provides comprehensive information on the specific components and conditions required for implementing these methods. [Extracted from the article]

Crinetics Pharmaceuticals Inc. has been granted a patent for formulations of a somatostatin modulator, a hormone that regulates the endocrine system. The patent describes a spray-dried solid dispersion that includes a specific compound and a polymer. The compound-to-polymer ratio can vary, and the dispersion can contain at least 5% of the compound. The patent also details a method of suppressing certain hormones in humans using a pharmaceutical composition, which involves orally administering the composition on an empty stomach before a meal. For more information, consult the patent filed by Hannah Bulovsky of Crinetics Pharmaceuticals Inc. [Extracted from the article]

The patent application titled "High Concentration Protein Formulations With Reduced Viscosity" discusses the challenges of highly concentrated protein-agent formulations, such as high viscosity and aggregation. The inventor proposes low-viscosity, high concentration therapeutic protein agent formulations that can be injected subcutaneously or intramuscularly. The application also addresses the importance of stability and ease of administration. The patent application describes a method for preparing a liquid formulation of protein agents with reduced viscosity, including the use of a buffer and a viscosity-reducing agent. The inventors also claim a method of administering the formulation, which includes specific concentrations of antibody agents and a viscosity-reducing agent. The formulation has a viscosity range of 1 cP to 100 cP at 25°C. The patent application provides further details and claims for the formulation and its components. [Extracted from the article]

A patent application titled "Ocular Compositions" has been published by the US Patent and Trademark Office. The application, filed by inventors Chirag Gujral, David Jones, and Raghu Raj Singh Thakur, proposes ocular compositions for drug delivery in the treatment of eye diseases. The compositions consist of polyalkylene glycol diacrylate or polyalkylene glycol dimethacrylate, along with either PCL or PLLA as biodegradable polymers. The compositions can be polymerized using light irradiation and can be formulated as nanoparticles or microparticles. The invention offers the potential for long-acting and controlled release delivery systems, reducing the need for frequent injections and improving patient compliance. [Extracted from the article]

A patent application has been filed for a transdermal delivery formulation that aims to effectively deliver therapeutic agents to targeted sites in the body. The formulation focuses on enhancing nitric oxide levels, which have systemic benefits such as reversing inflammation and protecting blood vessels. The application also discusses the role of CD38 in various disease states and proposes a transdermal formulation to reduce CD38 levels and promote the activity of NAD+ dependent sirtuins. The formulation aims to bypass the gut and liver, deliver the active agents directly into the plasma and blood cells, and repolarize activated immune cells. It includes curcuminoids and flavonoids for the treatment of various conditions and can be used for transdermal treatment of inflammatory conditions, prevention of endothelial dysfunction, treatment of dermatological conditions, and more. The formulation is designed for sustained transdermal delivery and can be used in a kit or nebulizer. The application also includes methods for treating diseases associated with elevated CD38 levels and reducing CD38 activities. [Extracted from the article]

Johnson & Johnson Consumer Inc. has been issued a patent for methods and compositions suitable for the treatment of acne. The patent describes a composition for the treatment of acne that includes glycolic acid, gluconolactone, mandelic acid, a glycol, and a salt-tolerant thickening polymer. The composition is designed to be efficacious and well-tolerated by the skin. The patent also includes claims for specific formulations and methods of treating skin using the composition. This information may be useful for library patrons researching acne treatments and skincare products. [Extracted from the article]

This document is a patent for biocompatible protein-based particles and methods of using them to treat and enhance the function of joints. The particles are made from soluble biocompatible proteins, glycosaminoglycans, and biocompatible solvents. They can be customized to incorporate pharmacologically active agents and other structural materials. The particles can be administered to the synovial space or the area proximal to the periosteum in joints, and they have the ability to act as a structural scaffold. The patent provides detailed claims and descriptions of the particles and their applications. [Extracted from the article]

A patent application by inventor Joel M. Friedman has been made available online, detailing a transdermal delivery system for enhancing systemic nitric oxide (NO) levels. The system aims to address bioavailability issues associated with delivering therapeutic agents to specific sites in the body. The formulation includes an NO booster and/or an NO precursor, a solvent, and optionally a fatty acid. The system has potential applications in treating various conditions, such as inflammatory diseases, dermatological conditions, pulmonary conditions, infections, and neurodegenerative diseases. The patent application provides detailed information on the formulation and its potential uses. [Extracted from the article]

Patheon Softgels Inc. has been issued a patent for Liquisoft capsules, which are chewable soft gelatin capsules. These capsules have a liquid fill and are designed to be chewed, sucked, or dissolved in the mouth. They are intended to provide a pleasant-tasting or refreshing experience and can be used for various purposes, such as cough and cold remedies, pain relief, nicotine replacement therapy, and gastrointestinal treatments. The patent describes the composition of the capsules, including the shell and the liquid matrix, as well as the inclusion of active pharmaceutical ingredients. [Extracted from the article]

A study conducted at Anhui University of Chinese Medicine in Hefei, People's Republic of China, has developed a novel modified chitosan that can effectively remove lead and cephalexin. Chitosan, a natural and non-toxic adsorbent, was modified with polypropylene glycol and itaconic anhydride to enhance its mechanical properties. The maximum adsorption capacities of lead and cephalexin were found to be 431.73 mg g(-1) and 153.72 mg g(-1), respectively. The study also discussed the possible adsorption mechanism of these substances. This research has been peer-reviewed and provides valuable insights into the field of obesity, fitness, and wellness. [Extracted from the article]

A patent has been issued to Albert Einstein College of Medicine for transdermal delivery formulations that enhance nitric oxide (NO) levels in the body. The formulations aim to address bioavailability issues and deliver therapeutic agents effectively to targeted sites. NO has systemic benefits, including reversing inflammation and preventing endothelial dysfunction. The patent describes various applications for the transdermal formulation, such as treating inflammatory conditions, preventing endothelial dysfunction, and treating pulmonary conditions. The formulation can also be used topically for dermatological conditions and loaded onto medical sponges for various uses. [Extracted from the article]

A method of producing a urine albumin detection test strip, comprising cutting the albumin detection test substrate produced according to the method of claim 1 and then attaching the albumin detection test substrate to a PVC sheet support. A method for producing an albumin detection test substrate comprising: (a) a single process of adding a surfactant, a sensitizer and an albumin indicator to a buffer solution to prepare an impregnation solution; and (b) impregnating a substrate with the impregnation solution and drying the substrate to obtain the albumin detection test substrate, wherein the buffer solution is prepared by mixing ethanol, citric acid and trisodium citrate, wherein the albumin indicator is 5',5"-dinitro-3',3",3,4,5,6-hexabromophenolsulfonephthalein, wherein the sensitizer is polypropylene glycol, and wherein the buffer solution is prepared by slowly mixing 20 to 40 parts by weight of citric acid and 10 to 30 parts by weight of trisodium citrate based on 100 parts by weight of ethanol. [Extracted from the article]

"Furthermore, additives, for example antistatic agents or colored pigments, can be introduced into the molten thermoplastic polymer or can be introduced into the polymer fiber during the multiple spinning process. "Modifying or equipping polymer fibers for the respective end use or for the necessary intermediate treatment steps, for example drawing and/or crimping, is usually carried out by applying suitable softening agents or dressings which are applied to the surface of the prepared polymer fibers or the polymer fibers to be treated. The multi-component polymer fiber as claimed in claim 1, characterized in that the thermoplastic polymer A and/or B is/are selected from the group formed by polylactic acids (PLA) as well as their copolymers, polyhydroxy fatty acid esters (PHF) as well as their copolymers, as well as blends of said polymers, or characterized in that at least the thermoplastic polymer A and/or the thermoplastic polymer B is/are selected from the group formed by melt spinnable synthetic biopolymers, wherein polycondensates and polymerisates from bio-based starting materials are particularly preferred. [Extracted from the article]

Keywords: Alkenes; Antibodies; Betaherpesvirinae; Biological Products; Biopharmaceutical Companies; Blood Proteins; Business; Connective Tissue Cells; Cytomegalovirus; DNA Viruses; Ethylene Glycols; Fibroblasts; Health and Medicine; Healthcare Biotechnology Companies; Herpesviridae; Herpesvirus; Herpesvirus Diseases and Conditions; Hydrocarbons; Immunization; Immunoglobulins; Immunology; Immunoproteins; Merck Sharp & Dohme LLC; Neutralizing Antibodies; Organic Chemicals; Polyenes; Polyethylene Glycols; Polyethylenes; Proteins; Serum Globulins; Vaccines; Viral; Virology; Virus EN Alkenes Antibodies Betaherpesvirinae Biological Products Biopharmaceutical Companies Blood Proteins Business Connective Tissue Cells Cytomegalovirus DNA Viruses Ethylene Glycols Fibroblasts Health and Medicine Healthcare Biotechnology Companies Herpesviridae Herpesvirus Herpesvirus Diseases and Conditions Hydrocarbons Immunization Immunoglobulins Immunology Immunoproteins Merck Sharp & Dohme LLC Neutralizing Antibodies Organic Chemicals Polyenes Polyethylene Glycols Polyethylenes Proteins Serum Globulins Vaccines Viral Virology Virus 2807 2807 1 09/25/23 20230929 NES 230929 2023 SEP 29 (NewsRx) -- By a News Reporter-Staff News Editor at Vaccine Weekly -- A patent application by the inventors Blue, Jeffrey Thomas (Telford, PA, US); Chen, Lorenzo H. (Hatfield, PA, US); Davis, Harrison Bradford (Lansdale, PA, US); Green-Trexler, Erin J. (Green Lane, PA, US); Isopi, Lynne Ann (Quakertown, PA, US); Medi, Muneeswara Babu (Chalfont, PA, US); Pixley, Heidi Joanne (Glenside, PA, US), filed on November 30, 2022, was made available online on September 7, 2023, according to news reporting originating from Washington, D.C., by NewsRx correspondents. The formulation of claim 1 that is in a dried solid form comprising a weight ratio of about CMV 1, histidine 6-108, NaCl 7-123, sucrose 150-2520, propylene glycol 8-140, and sodium carboxymethylcellulose 8-140. [Extracted from the article]

A polyurethane film formed of the aqueous polyurethane resin composition according to claim 1. The aqueous polyurethane resin composition according to claim 1, wherein a content of free isocyanate groups in the isocyanate-terminated prepolymer is 0.2 to 3.5% by mass. "Advantageous Effects of Invention "The present invention makes it possible to obtain an aqueous polyurethane resin composition which has favorable film formability and makes it possible to obtain a polyurethane film combining favorable flexibility, tensile strength at break, and elongation at break.". [Extracted from the article]

"Many protein agent-based therapeutics are administered intravenously (IV); in some instances IV administration is required or useful given the high doses being administered, which can often be in a range of about 100 mg to about 1 g of protein agent per injection. The following quote was obtained by the news editors from the background information supplied by the inventors: "Protein agent-based therapeutics, including antibody therapeutics, are widely used for a variety of human diseases, and marketing approvals increase every year. Keywords: Amino Acids; Antibodies; Bhami's Research Laboratory Pvt. Ltd.; Blood Proteins; Business; Cyclic Amino Acids; Drugs and Therapies; Essential Amino Acids; Health and Medicine; Histidine; Immunoglobulins; Immunology; Indicators and Reagents; Proteins; Reducing Agents; Therapeutics; Therapy EN Amino Acids Antibodies Bhami's Research Laboratory Pvt. Ltd. Blood Proteins Business Cyclic Amino Acids Drugs and Therapies Essential Amino Acids Health and Medicine Histidine Immunoglobulins Immunology Indicators and Reagents Proteins Reducing Agents Therapeutics Therapy 3414 3414 1 09/19/23 20230919 NES 230919 2023 SEP 22 (NewsRx) -- By a News Reporter-Staff News Editor at Pharma Business Week -- A patent by the inventor Shenoy, Bhami (Mangalore, IN), filed on February 11, 2020, was published online on August 29, 2023, according to news reporting originating from Alexandria, Virginia, by NewsRx correspondents. [Extracted from the article]

A method of making a pharmaceutical composition comprising one or more active pharmaceutical ingredients (APIs) with one or more pharmaceutically acceptable excipients by thermokinetic compounding, comprising thermokinetic processing the one or more APIs with the one or more pharmaceutically acceptable excipients until melt blended into a composite. A pharmaceutical composition comprising one or more active pharmaceutical ingredients (APIs) with one or more pharmaceutically acceptable excipients wherein the composition is a homogenous, heterogenous, or heterogenously homogenous composition in which the glass transition temperature is significantly higher than the glass transition temperature of an identical formulation of identical active pharmaceutical ingredients and pharmaceutically acceptable excipients processed thermally. A pharmaceutical composition comprising one or more active pharmaceutical ingredients (APIs) with one or more pharmaceutically acceptable excipients wherein the composition is a homogenous, heterogenous, or heterogenously homogenous composition which has a single glass transition temperature, wherein an identical formulation of identical active pharmaceutical ingredients and pharmaceutically acceptable excipients processed thermally has two or more glass transition temperatures. A pharmaceutical composition comprising one or more active pharmaceutical ingredients (APIs) with one or more pharmaceutically acceptable excipients processed into a composite, wherein at least one of the APIs is thermally labile, wherein the composite is a homogenous, heterogenous, or heterogenously homogenous composition which has a less than about 1.0% degradation products of each thermally labile API. [Extracted from the article]

Anions, Calcium Phosphates, Composites Science, Dentistry, Health and Medicine, Hydrocarbons, Inorganic Chemicals, Organic Chemicals, Phosphates, Phosphoric Acids, Phosphorus Compounds, Polyenes, Polypropylenes, Science, Calcium Compounds Keywords: Anions; Calcium Compounds; Calcium Phosphates; Composites Science; Dentistry; Health and Medicine; Hydrocarbons; Inorganic Chemicals; Organic Chemicals; Phosphates; Phosphoric Acids; Phosphorus Compounds; Polyenes; Polypropylenes; Science EN Anions Calcium Compounds Calcium Phosphates Composites Science Dentistry Health and Medicine Hydrocarbons Inorganic Chemicals Organic Chemicals Phosphates Phosphoric Acids Phosphorus Compounds Polyenes Polypropylenes Science 6237 6237 1 05/15/23 20230519 NES 230519 2023 MAY 19 (NewsRx) -- By a News Reporter-Staff News Editor at Health & Medicine Week -- A new study on composites science is now available. [Extracted from the article]

Drugs that may be incorporated into the pouches include antimicrobial agents, antibiotics, anesthetics, anti-inflammatory agents, anti-fibrotic agents, anti-scarring agents, and leukotrienes. Keywords: Antibacterials; Antibiotics; Antimicrobials; Business; Cardiology; Drugs and Therapies; Health and Medicine; Medical Devices; Pacemakers; Risk and Prevention; Tepha Inc EN Antibacterials Antibiotics Antimicrobials Business Cardiology Drugs and Therapies Health and Medicine Medical Devices Pacemakers Risk and Prevention Tepha Inc 1225 1225 1 04/17/23 20230417 NES 230417 2023 APR 17 (NewsRx) -- By a News Reporter-Staff News Editor at Pharma Business Week -- Tepha Inc. (Lexington, Massachusetts, United States) has been issued patent number 11612754, according to news reporting originating out of Alexandria, Virginia, by NewsRx editors. Antibacterials, Antibiotics, Antimicrobials, Business, Cardiology, Drugs and Therapies, Health and Medicine, Medical Devices, Pacemakers, Risk and Prevention, Tepha Inc. [Extracted from the article]

The solution of claim 1, wherein the polyanion comprises a polyphosphate, wherein the polyphosphate comprises a natural polymer or a synthetic polymer. The solution of claim 1, wherein the monovalent ions in the solution are sodium ions and chloride ions. The solution of claim 1, wherein the concentration of the monovalent ions in the solution is 1.5 to 10 times greater than the concentration of the monovalent ions at the application site. [Extracted from the article]